Document:

Letter Agreement

 Exhibit 10.1 

AGREEMENT RELEVANT TO THE SETTLEMENT AND LICENSE AGREEMENT 

This AGREEMENT RELEVANT TO THE SETTLEMENT AND LICENSE AGREEMENT (“Relevant Agreement”) is made this 23rd day of September, 2010
(“Relevant Agreement Effective Date”) by and between Trimeris, Inc. (“Trimeris”), and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (the latter two companies collectively, “Roche”). 

WHEREAS, Trimeris and Roche (collectively the “Parties”) have previously entered into a Development and
License Agreement (including its Appendices) dated as of the
1st day of July 1999, by and between Trimeris and Roche
(the “Development and License Agreement”), as amended by Amendment to the Development and License Agreement (“First Amendment”) executed July 12, 2004 and effective January 5, 2004, and the Letter of Amendment
(“Second Amendment”) effective September 20, 2005; 
 WHEREAS, Trimeris, Roche and certain affiliates of Roche
are defendants in a law suit (the “Novartis Litigation”) brought by plaintiff Novartis Vaccines and Diagnostics, Inc. (“Novartis”), Civil Action No. 5:09-CV-00519-F, United States District Court for the Eastern District of
North Carolina; 
 WHEREAS, the plaintiff and defendants in the Novartis Litigation are currently in settlement negotiations;

 WHEREAS, under the provisions of Section 8.4 of the Agreement, neither Roche nor Trimeris may settle the Novartis
Litigation without the consent of the other; and 
 WHEREAS, Roche and Trimeris desire to settle the Novartis Litigation under
reasonable terms and to evenly share the settlement costs. 
 NOW, THEREFORE, in consideration for the foregoing promises and
for good and valuable consideration, the receipt and sufficiency which are hereby acknowledged, the Parties hereby agree as follows: 
  

	 	1.	Any capitalized term not otherwise defined herein shall have the meaning ascribed to it in the Agreement (as amended by the First Amendment and Second Amendment).

  

	 	2.	If Trimeris and Roche agree to settlement terms in the Novartis Litigation that are acceptable to Novartis (“Settlement and License Agreement”), then on the
date (if any) that the Settlement and License Agreement is executed by all parties and approved by the District Court of North Carolina responsible for the Novartis Litigation, 

 

 - 1 - 

	 	a)	Any obligation of Trimeris to repay to Roche any Trimeris Deferred Expenses (as defined in the First Amendment) shall be released and discharged without any further
action being required by any party, and 

  

	 	b)	Trimeris shall pay fifty percent (50%) of the following as they become due: (i) all of the outside law firm fees and disbursements and court fees and expenses
associated with the Novartis Litigation (with each of Roche and Trimeris continuing to be responsible for its respective internal costs and expenses associated with the Novartis Litigation), and (ii) the settlement with Novartis.

  

	 	3.	After Trimeris and Roche each pay the Past Settlement Amount as set forth in the Settlement and License Agreement, Roche will handle paying Novartis the royalty due
under the Settlement and License Agreement, and offset Trimeris' share of such royalty payments from payments otherwise payable from Roche to Trimeris under the Development and License Agreement. Any claim by Novartis arising from or related to
Roche’s payment of settlement and royalty amounts to Novartis pursuant to settlement of the Novartis Litigation shall be handled solely by Roche at the sole expense of Roche. 

 

	 	4.	Except as specifically provided in this Relevant Agreement, the terms of the Development and License Agreement (including its Appendices), as expressly amended by the
First Amendment and Second Amendment, shall remain in full force and effect. All references contained in the Development and License Agreement shall be deemed to include the provisions of this Relevant Agreement. This Relevant Agreement, together
with the Development and License Agreement (including its Appendices), First Amendment and Second Amendment, shall constitute the entire understanding between the parties with respect to the subject matter hereof and may be modified only in a
writing signed by the parties. 

 Remainder of page intentionally left blank. 

 

 - 2 - 

 IN WITNESS WHEREOF, the parties have executed this Relevant Agreement to be effective as of
the Relative Agreement Effective Date. 
  

									
	TRIMERIS, INC.	  		  	HOFFMANN-LA ROCHE INC.
					
	By:	  	 /s/ Martin A. Mattingly
	  		  	By:	  	 /s/ Gerorge W. Johnston

		  	Martin A. Mattingly	  		  		  	Gerorge W. Johnston
		  	Chief Executive Officer	  		  		  	Vice President
				
		  		  		  	F. HOFFMANN-LA ROCHE LTD
					
		  		  		  	By:	  	 /s/ Robert Ferraro

		  		  		  		  	Robert Ferraro
		  		  		  		  	Attorney at Law
					
		  		  		  	By:	  	 /s/ Ruben Perrin

		  		  		  		  	Dr. Ruben Perrin
		  		  		  		  	Legal Counsel

  

 - 3 -fs1a3ex10xxxiv_keyuan.htm

Exhibit 10.34

 

CONFIDENTIALITY AGREEMENT

This CONFIDENTIALITY AGREEMENT (“Agreement”) is entered into this 10th day of May, 2007 by and between Ningbo Keyuan Plastic Co., Ltd., a PRC company located at Qingshi Industrial Zone, the Economy & Technology Development District, Ningbo, Zhejiang Province, 315803  ("Party A"), and the employee of Party A as provided hereunder ("Party B").

 

WITNESSETH

 

      WHEREAS, the parties hereto desire to enter into this Agreement to define and set forth the confidentiality obligations assumed by Party B.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth below, it is hereby covenanted and agreed by both parties as follows:

Confidential Information

                Party B will not, directly or indirectly, disclose to any third party or use any Keyuan confidential information during or after the term of the employment. Notwithstanding the two (2) year limitation in the “Non-Compete” section, the “Non-Compete” and “Non-Use” obligations shall last until the underlying confidential information becomes available to the public other than as a result of Party B’s disclosure. Such “Non-Compete” and “Non-Use” obligations also apply to any information acquired by Party B from any third party which assumes confidentiality obligation to Party A. In addition, as the employee of Party A, Party B will not use or disclose to Party A any confidential information which belongs to Party B’s prior employer or any other third party. Party B has submitted or will submit a copy of any agreement between Party B and any of his prior employers or any third party which might affect the employment relationship between Party A and Party B.

Intellectual Property

                For the purpose of this Agreement, “Confidential Information” shall mean any invention, discovery, publication, computer program, integrated circuit design, trademark or any other intangible assets exclusively owned by Party A and furnished to Party B, including any such intangible assets that are developed or designed by Party B during Party B’s personal time, or although developed by Party B during his personal time, it is (1) related to Party A’s business or Party A’s actual or potential research and development, or (2) developed when Party B is working for Party A.

 

                All intellectual property developed by Party B related to Party A’s products during the term of the employment or within one (1) year after Party B’s termination of his employment in Party A shall belong to Party A.

  

                All intellectual property developed by Party B during the term of the employment or within one (1) year after Party B leaves Party A, which related to Keyuan products and are developed by Party B, either individually or together with other people, remains the property of Party A.

                Party B will keep a precise written record of all intellectual property relating to Keyuan products which are developed by Party B individually or with other people, and disclose to Party A of such record.

Intellectual Property Rights

                Party B will transfer all his intellectual property rights related to Keyuan products to Party A. Party B will also prepare all related documents to protect such intellectual property rights worldwide, sign and deliver to Party A all documents necessary for patent application transfer, patent transfer and copyright registration. Party A will compensate Party B for the time and expense incurred in assisting Party B in connection with such intellectual property issues after the termination of Party B’s services.

  

  

  

Assets

                Party B acknowledges that all the blueprints, manuals, reports, notes, photos, client lists, schedules, computer program and data and any other media containing confidential information of Party A in any form are the properties of Party A and upon the termination of Party B’s employment Party B will return all such data and information to Party A.

Non-Compete

                 For a period ending two (2) years after the termination date of Party B’s employment, Party B will not directly or indirectly engage in any business activity in any area related to Party A’s confidential information which Party B have engaged in during the last five (5) years of Party B’s employment.

 

Intervention of Business

                 Party B will not directly or indirectly solicit, persuade, hire or in any other way cause any of Party A’s employees to terminate their employment with Party A. Party B will not intervene or attempt to intervene any contractual relationship or other relationship in which Party A is a party.

Data Use and Protection

                 Party B hereby authorizes Party A to store or transfer any of Party B’s family or personal information which is collected by Party A to other related company or any third party service provider for the business management purpose of Party A.

Dated this 10th day of May, 2007.

___________________________________________

Party A: Ningbo Keyuan Plastic Co., Ltd.

___________________________________________

Party B:  Jingtao Ma

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}]]